Improve the Performance and Lower the Costs of ODT Drug Applications
J.T.Baker® PanExcea™ MC200G performance excipient from Avantor™ Performance Materials (formerly Mallinckrodt Baker) is engineered to reduce your cost-per-tablet.
J.T.Baker® PanExcea MC200G performance excipient from Avantor Performance Materials (formerly Mallinckrodt Baker) is an orally disintegrating tablet (ODT) building block enabling formulators to develop a direct compression ODT that disintegrates rapidly while offering good taste and texture. PanExcea™ MC200G offers a unique, dense spherical particle shape and morphology to maximize API loading capacity, blend flowability and taste-masking.
An excipient-based solution, PanExcea MC200G is also engineered to reduce cost-per-tablet because it can be produced using standard manufacturing and packaging equipment. This reduces or eliminates the costs of ODT technology licensing and new equipment investment. Read more.
Learn more: www.mallbaker.com/panexcea
Avantor Performance Materials
222 Red School Lane
Phillipsburg, NJ 08865
1-855-AVANTOR (within U.S.)
1-908-859-2151 (outside U.S.)
Fax: 908-859-6905
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
